CONSULTATION

PHARMAC
Pharmaceutical Management Agency

08 July 2013

Proposal for a sole supply arrangement for fentanyl patches

PHARMAC is seeking feedback on a proposal to list a new brand of fentanyl patches, Fentanyl Sandoz, under a sole supply arrangement with Novartis New Zealand Limited. This proposal arose from a request for proposals (RFP) issued by PHARMAC in which pharmaceutical companies were invited to compete to be the sole subsidised supplier of fentanyl patches.

This proposal would provide savings to the Combined Pharmaceutical Budget and would result in a change in the funded brand of fentanyl patches. In summary:

- Fentanyl Sandoz would be listed in the Pharmaceutical Schedule as soon as possible following Medsafe registration;
- from the date of listing Fentanyl Sandoz, the currently funded brand of fentanyl patches, Mylan Fentanyl Patch, would remain fully subsidised for 6 months, after which time Mylan Fentanyl Patch would be delisted;
- following the delisting of Mylan Fentanyl Patch, Fentanyl Sandoz would be the only subsidised brand of fentanyl patches until 30 June 2016.

It is anticipated that if this proposal is approved it would be implemented towards the end of this year or early next year.

Further details of the proposal can be found on the following pages.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **5:00 pm Monday 22 July 2013** to:

Geraldine MacGibbon	Email: geraldine.macgibbon@pharmac.govt.nz
Therapeutic Group Manager	Fax: 04 460 4995
PHARMAC	Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC's Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant

Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

Details of the proposal

- Fentanyl Sandoz fentanyl patches would be listed in Section B, and in Part II of Section H, of the Pharmaceutical Schedule as soon as is practicable following Medsafe registration, at the following prices and subsidies (ex-manufacturer, excluding GST):

Strength	Pack Size	Current price and subsidy (Mylan Fentanyl Patch)	Proposed price and subsidy (Fentanyl Sandoz)
12.5 mcg per hour*	5	$8.90	$2.92
25 mcg per hour	5	$9.15	$3.66
50 mcg per hour	5	$11.50	$6.64
75 mcg per hour	5	$13.60	$9.18
100 mcg per hour	5	$14.50	$11.29

*Note that this strength of Fentanyl Sandoz is recorded as 12 mcg per hour in the application section of the Medsafe website but it actually delivers 12.5 mcg per hour.

- From the date of listing Fentanyl Sandoz there would be a 6-month transition period during which Mylan Fentanyl Patch would remain fully subsidised. After this 6-month transition period, Mylan Fentanyl Patch would be delisted from the Pharmaceutical Schedule.
- Following the delisting of Mylan Fentanyl Patch, Fentanyl Sandoz would be the sole subsidised brand of fentanyl patches in the community, and would have Hospital Supply Status, until 30 June 2016.
- The Fentanyl Sandoz brand of fentanyl patches is a matrix formulation. It is currently registered in Australia and the European Union and was submitted to Medsafe in June 2013.